Sugi Predict

Sugi Predict / Compounds / SCHEMBL3537217

SCHEMBL3537217

SCHEMBL3537217

N#Cc1cccc(N2CCCC2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DRD2 P14416 4/20 0.74
▸ DRD3 P35462 3/20 0.74
▸ NOTUM Q6P988 2/20 0.54
▸ ALOX5 P09917 1/20 0.53
▸ C1S P09871 1/20 0.51
▸ NSD2 O96028 1/20 0.47
▸ PRMT6 Q96LA8 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.47
▸ MEN1 O00255 1/20 0.47
▸ ALDH1A1 P00352 1/20 0.47
▸ GAA P10253 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ MLYCD O95822 1/20 0.47
▸ SLC2A1 P11166 1/20 0.47
▸ SLC2A2 P11168 1/20 0.47
▸ SLC2A3 P11169 1/20 0.47
▸ DHFR P00374 1/20 0.46
▸ GRM5 P41594 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29809089 1.00 DRD2 (0.74) DRD2DRD3NOTUMALOX5C1S
SCHEMBL4468086 0.98 DRD2 (0.72) DRD2DRD3NOTUMALOX5C1S
SCHEMBL15800697 0.92 DRD2 (0.79) DRD2DRD3NOTUMALOX5C1S
SCHEMBL28017895 0.90 DRD2 (0.62) DRD2DRD3NOTUMALOX5C1S
SCHEMBL20159295 0.87 DRD2 (0.88) DRD2DRD3NOTUMALOX5ALDH1A1
Hydrochloric Acid SCHEMBL20141804 0.85 DRD2 (0.85) DRD2DRD3NOTUMALOX5ALDH1A1
SCHEMBL30855584 0.85 DRD2 (1.00) DRD2DRD3NOTUMALOX5ALDH1A1
SCHEMBL2729148 0.85 DRD2 (0.70) DRD2DRD3NOTUMALOX5C1S
SCHEMBL249732 0.85 DRD2 (1.00) DRD2DRD3NOTUMALOX5ALDH1A1
SCHEMBL21360372 0.84 DRD2 (0.59) DRD2DRD3NOTUMALOX5C1S

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240150346-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF INNOVSTONE THERAPEUTICS LIMITED (CN) 2024-05-09 — — US disclosed
CN-114805341-B Aromatic heterocyclic compound, and preparation method and application thereof 上海翊石医药科技有限公司 2023-12-08 — — CN disclosed
WO-2022161420-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊石医药科技有限公司 2022-08-04 — — WO disclosed
WO-2022161420-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF 上海翊石医药科技有限公司 2022-08-04 — — WO disclosed
CN-114805341-A Aromatic heterocyclic compounds and preparation method and application thereof 上海翊石医药科技有限公司 2022-07-29 — — CN disclosed
EP-2900642-B1 SUBSTITUTED SULFONAMIDE COMPOUNDS HOFFMANN LA ROCHE (CH) 2018-02-28 — — EP disclosed
EP-2900642-B1 SUBSTITUTED SULFONAMIDE COMPOUNDS HOFFMANN LA ROCHE (CH) 2018-02-28 — — EP disclosed
EP-2632255-B1 DIAZENIUMDIOLATE HETEROCYCLIC DERIVATIVES MERCK SHARP & DOHME (US) 2017-06-21 — — EP disclosed
US-9580411-B2 Substituted sulfonamide compounds HOFFMANN-LA ROCHE INC. (US) 2017-02-28 — — US disclosed
US-9580411-B2 Substituted sulfonamide compounds HOFFMANN-LA ROCHE INC. (US) 2017-02-28 — — US disclosed
EP-1354887-A1 Ligands for metals and improved metal-catalyzed processes based thereon Massachusetts Insitute of Technology (US) 2003-10-22 — — EP disclosed
US-6617346-B1 Inhibit the interaction of MDM2 protein with a p53-like peptide and have antiproliferative activity HOFFMANN-LA ROCHE INC. 2003-09-09 — — US disclosed
US-20030153580-A1 Such as 1-(4,5-Bis-(4-chloro-phenyl)-2-(2,4-dimethoxy-phenyl)-4,5-dihydro-imidazol-1-yl)-2-methyl-propan-1-one which inhibits the interaction of MDM2 protein with p53-like peptide; antiproliferative agents KONG NORMAN (US) 2003-08-14 — — US disclosed
WO-2003051359-A1 CIS-2,4,5- TRIPHENYL-IMIDAZOLINES AND THEIR USE IN THE TREATMENT OF TUMORS F.HOFFMANN-LA ROCHE AG (CH) 2003-06-26 — — WO disclosed
WO-2003051360-A1 CIS-IMIDAZOLINES AS MDM2 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2003-06-26 — — WO disclosed
US-6579872-B1 Such as TNF, in particular of TNF alpha, and various interleukins, in particular IL-1; N-(5-(4-(3-hydroxypropoxy)benzamido)-2-methylphenyl)-3,4-dimethoxybenzamide ASTRAZENECA AB (SE) 2003-06-17 — — US disclosed
EP-1097158-A2 LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2001-05-09 — — EP disclosed
EP-1077931-A1 BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES AstraZeneca AB (SE) 2001-02-28 — — EP disclosed
WO-2000002887-A2 LIGANDS FOR METALS AND METAL-CATALYZED PROCESSES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2000-01-20 — — WO disclosed
WO-1999059959-A1 BENZAMIDE DERIVATIVES FOR THE TREATMENT OF DISEASES MEDIATED BY CYTOKINES ASTRAZENECA AB (SE) 1999-11-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240150346-A1 CLASS OF HETEROAROMATIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF TLR7, TLR1, TLR8 DRD2 2701/4885DRD3 2946/4885NOTUM 238/4885
US-20030153580-A1 Such as 1-(4,5-Bis-(4-chloro-phenyl)-2-(2,4-dimethoxy-phenyl)-4,5-dihydro-imidazol-1-yl)-2-methyl-propan-1-one which inhibits the interaction of MDM2 protein with p53-like peptide; antiproliferative agents TP53, MDM2, TP53BP1 DRD2 4711/4885DRD3 4682/4885NOTUM 4105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.